Searchable abstracts of presentations at key conferences in endocrinology

ea0005p185 | Neuroendocrinology and Behaviour | BES2003

Abnormal endocrine tests in chronic pain require investigation and are not the result of opioid analgesia

Merza Z , Edwards N , Walters S , Newell-Price J , Ross R

Background: Anecdotally patients with chronic pain on opioid analgesia have functional hypopituitarism, and studies in opioid addicts show suppressed pituitary function. We conducted a prospective observational study to determine the endocrine status of patients with chronic pain on opioid analgesia. Methods: 37 consecutive patients with chronic back pain attending the pain clinic were enrolled. 22 patients (age 45+/-9 years) were on long-term opioid analgesia and 15 (age 53 +...

ea0002p95 | Steroids | SFE2001

THE UTILITY OF BASAL ACTH MEASUREMENT DURING MORNING SYNACTHEN TESTING

Chaggar P , Price A , Walters S , Ross R , Weetman A , Newell-Price J

Background: The 250microgram synacthen test may give false negative responses, and will not allow easy discrimination between primary and secondary dysfunction. Furthermore, the use of synacthen is contra-indicated on the data sheet in certain common conditions such as asthma, and may not easily be interpreted in women taking oral oestrogen. Some patients with incipient adrenal failure may have elevated plasma ACTH, whilst passing the synacthen test. We have routinely measured...

ea0005p181 | Neuroendocrinology and Behaviour | BES2003

A randomised double-blind cross-over study of GH treatment in patients over 60 years

Mah P , Walters S , Newell-Price J , Webster J , Doane A , Ibbotson V , Hosker J , Jones T , Ho K , Eastell R , Ross R

AIM: To assess efficacy of GH replacement and safety of stopping treatment in patients aged over 60 years.METHODS: GH-deficient patients were started on GH 0.13 miligram per day and the dose titrated over 4 months to a serum IGF-1 in the upper half of the age-related normal range. After 4 months titration, patients were randomised to either continuing GH or placebo in a double-blind, cross-over study with 2 x 4 month periods of either GH or placebo treatment.RESULTS: 1...